Executive Order 14293: Regulatory Relief To Promote Domestic Production of Critical Medicines

This executive order aims to eliminate regulatory roadblocks that slow the domestic production of critical medicines. It directs multiple federal agencies—including the FDA, EPA, and Army Corps of Engineers—to streamline inspections, permits, and reviews that affect pharmaceutical manufacturing. The goal is to reduce delays and uncertainty, strengthen national security, and bolster the U.S. supply chain for essential drugs and raw materials. The order prioritizes faster facility approvals, better foreign inspection practices, and centralized coordination to boost investment in American pharmaceutical infrastructure.